

DAFTAR PUSTAKA

- Adhikari, S. P. *et al.* (2020) 'Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: A scoping review', *Infectious Diseases of Poverty*. BioMed Central Ltd., pp. 1–12. doi: 10.1186/s40249-020-00646-x.
- Agarwal, N. and Dewan, P. (2016) 'Writing a review article: Making sense of the jumble', *Indian Pediatrics*, 53(8), pp. 715–720. doi: 10.1007/s13312-016-0915-z.
- Aromataris, E. and Pearson, A. (2014) 'The systematic review: An overview', *American Journal of Nursing*. Lippincott Williams and Wilkins, pp. 53–58. doi: 10.1097/01.NAJ.0000444496.24228.2c.
- Boruta, T. and Bizukojc, M. (2017) 'Production of lovastatin and itaconic acid by *Aspergillus terreus*: a comparative perspective', *World Journal of Microbiology and Biotechnology*. Springer Netherlands. doi: 10.1007/s11274-017-2206-9.
- Brunton, L., Knollman, B. and Hilal-Dandan, R. (2017) *Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition*. McGraw-Hill Education. Available at: <https://books.google.co.id/books?id=yAg7DwAAQBAJ>.
- Bui, L. T. *et al.* (2021) 'Chronic lung diseases are associated with gene expression programs favoring SARS-CoV-2 entry and severity', *Nature Communications* 2021 12:1, 12(1), pp. 1–13. doi: 10.1038/s41467-021-24467-0.
- Burhan, E., Isbaniah, F., Susanto, A. D., Nasution, S. A., *et al.* (2020) *Pedoman Tatalaksana COVID-19*. 3rd edn. Jakarta: Perhimpunan Dokter Paru Indonesia, Perhimpunan Dokter Spesialis Kardiovaskular Indonesia, Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia, Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia, Ikatan Dokter Anak Indonesia.
- Burhan, E., Isbaniah, F., Susanto, A. D., Aditama, T. Y., *et al.* (2020) *Pneumonia COVID-19, Diagnosis & Penatalaksanaan di Indonesia*. Jakarta: Perhimpunan Dokter Paru Indonesia.
- Cascella, M. *et al.* (2020) *Features, Evaluation and Treatment Coronavirus (COVID-19)*, *StatPearls*. StatPearls Publishing. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/32150360> (Accessed: 17 June 2021).
- Castiglione, V. *et al.* (2020a) 'Statin therapy in COVID-19 infection', *European*

Mawar Izzati Nadilla, 2023

PENGARUH PENGGUNAAN STATIN TERHADAP TINGKAT KEPARAHAN COVID-19 DENGAN KOMORBIDITAS: Sebuah Tinjauan Sistematis

UPN Veteran Jakarta, Fakultas Kedokteran, Program Studi Kedokteran Program Sarjana
[www.upnvj.ac.id – www.library.upnvj.ac.id – www.repository.upnvj.ac.id]

- Heart Journal - Cardiovascular Pharmacotherapy*. Oxford University Press, pp. 258–259. doi: 10.1093/EHJCVP/PVAA042.
- Castiglione, V. *et al.* (2020b) ‘Statin therapy in COVID-19 infection’, *European Heart Journal - Cardiovascular Pharmacotherapy*, 6(4), pp. 258–259. doi: 10.1093/EHJCVP/PVAA042.
- ‘Coronavirus Disease 2019 (COVID-19)’ (2020) *Journal of Midwifery and Women’s Health*. John Wiley and Sons Inc, pp. 833–834. doi: 10.1111/jmwh.13196.
- Ejaz, H. *et al.* (2020) ‘COVID-19 and comorbidities: Deleterious impact on infected patients’, *Journal of Infection and Public Health*, 13(12), p. 1833. doi: 10.1016/J.JIPH.2020.07.014.
- Fan, Y. *et al.* (2020) ‘Association of Statin Use With the In-Hospital Outcomes of 2019-Coronavirus Disease Patients: A Retrospective Study’, *Frontiers in Medicine*, 7, p. 584870. doi: 10.3389/FMED.2020.584870.
- Feingold, K. R. (2020) ‘Cholesterol Lowering Drugs -Endotext - NCBI Bookshelf’, in Feingold, K. R. *et al.* (eds). MDText.com, Inc. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK395573/> (Accessed: 28 April 2021).
- Ganjali, S. *et al.* (2020) ‘Statins, COVID-19, and coronary artery disease: killing two birds with one stone’, *Metabolism: Clinical and Experimental*, 113, p. 154375. doi: 10.1016/j.metabol.2020.154375.
- Gao, C. *et al.* (2020) ‘Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study’, *European Heart Journal*, 41(22), pp. 2058–2066. doi: 10.1093/EURHEARTJ/EHAA433.
- Grudzinska, F. S. *et al.* (2017) ‘Statin therapy in patients with community-acquired pneumonia’, *Clinical Medicine, Journal of the Royal College of Physicians of London*, 17(5), pp. 403–407. doi: 10.7861/clinmedicine.17-5-403.
- Guan, W. *et al.* (2020) ‘Clinical Characteristics of Coronavirus Disease 2019 in China’, *New England Journal of Medicine*, 382(18), pp. 1708–1720. doi: 10.1056/nejmoa2002032.
- Gunawan, S. G. *et al.* (2016) *Farmakologi dan Terapi Edisi 6*. Edisi 6. Jakarta: Badan Penerbit FKUI.
- Gupta, A. *et al.* (2020a) ‘Association Between Antecedent Statin Use and Decreased Mortality in Hospitalized Patients with COVID-19.’, *Research square*. doi: 10.21203/rs.3.rs-56210/v1.

- Gupta, A. *et al.* (2020b) ‘Association Between Antecedent Statin Use and Decreased Mortality in Hospitalized Patients with COVID-19.’, *Research square*. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/32818209> (Accessed: 3 August 2021).
- Hu, B. *et al.* (2021) ‘Characteristics of SARS-CoV-2 and COVID-19’, *Nature Reviews Microbiology*. Nature Research, pp. 141–154. doi: 10.1038/s41579-020-00459-7.
- Ikari, Y. *et al.* (2021) ‘Association between statin use prior to admission and lower coronavirus disease 2019 (COVID-19) severity in patients with cardiovascular disease or risk factors’, *Circulation Journal*, 85(6), pp. 939–943. doi: 10.1253/CIRCJ.CJ-21-0087.
- Jebril, N. (2020) ‘World Health Organization Declared a Pandemic Public Health Menace: A Systematic Review of the Coronavirus Disease 2019 “COVID-19”’, *SSRN Electronic Journal*. doi: 10.2139/ssrn.3566298.
- Jin, H. *et al.* (2020) ‘Altered Lipid Profile is a Risk Factor for the Progression and Recurrence of COVID-19: From Two Retrospective Cohorts’. doi: 10.21203/rs.3.rs-60159/v1.
- Jin, Y. *et al.* (2020) ‘Virology, epidemiology, pathogenesis, and control of covid-19’, *Viruses*. MDPI AG, p. 372. doi: 10.3390/v12040372.
- Joensen, L. E. *et al.* (2020) ‘Diabetes and COVID-19: psychosocial consequences of the COVID-19 pandemic in people with diabetes in Denmark—what characterizes people with high levels of COVID-19-related worries?’, *Diabetic Medicine*, 37(7), pp. 1146–1154. doi: 10.1111/DME.14319.
- Judson, G. L. *et al.* (2020) ‘Cardiovascular Implications and Therapeutic Considerations in COVID-19 Infection’, *Cardiology and Therapy*, 9(2), pp. 293–305. doi: 10.1007/s40119-020-00184-5.
- Karyono, D. R. and Wicaksana, A. L. (2020) ‘Current prevalence, characteristics, and comorbidities of patients with COVID-19 in Indonesia’, *Journal of Community Empowerment for Health*, 3(2), pp. 77–84. doi: 10.22146/jcoemph.57325.
- Katzung, B. G. *et al.* (2012) *Basic and Clinical Pharmacology 12/E*. McGraw-Hill Education (Basic and Clinical Pharmacology). Available at: <https://books.google.co.id/books?id=8r81icoTvDIC>.
- Katzung, B. G., Masters, S. B. and Trevor, A. J. (2012) *Basic and Clinical Pharmacology 12/E Inkling (ENHANCED EBOOK)*. McGraw-Hill Education (LANGE Basic Science). Available at: <https://books.google.co.id/books?id=Oig2eTjI1VAC>.

- Krishnan, G. and Subawa, A. N. (2018) 'Prevalence of diabetic retinopathy among diabetes mellitus type 2 patients at Diabetes Center of Sanglah General Hospital, Bali', *Intisari Sains Medis*, 9(1). doi: 10.15562/ISM.V9I1.155.
- Kupecz, D. (1997) 'Atorvastatin: a new agent for hyperlipidemia.', *The Nurse practitioner*, 22(11), pp. 87–8, 90, 93. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9403876> (Accessed: 29 April 2021).
- Li, X. *et al.* (2020) 'Molecular immune pathogenesis and diagnosis of COVID-19', *Journal of Pharmaceutical Analysis*. Xi'an Jiaotong University, pp. 102–108. doi: 10.1016/j.jpha.2020.03.001.
- Li, X., Li, T. and Wang, H. (2020) 'Treatment and prognosis of COVID-19: Current scenario and prospects (Review)', *Experimental and Therapeutic Medicine*, 20(6), pp. 1–1. doi: 10.3892/etm.2020.9435.
- Lin, J. *et al.* (2021) 'Chronic liver disease not a significant comorbid condition for COVID-19', *Scientific Reports 2021 11:1*, 11(1), pp. 1–6. doi: 10.1038/s41598-021-91238-8.
- Lohia, P., Kapur, S., Benjaram, S., Pandey, A., *et al.* (2021) 'Metabolic syndrome and clinical outcomes in patients infected with COVID-19: Does age, sex, and race of the patient with metabolic syndrome matter?', *Journal of Diabetes*, 13(5), pp. 420–429. doi: 10.1111/1753-0407.13157.
- Lohia, P., Kapur, S., Benjaram, S., Cantor, Z., *et al.* (2021) 'Statins and clinical outcomes in hospitalized COVID-19 patients with and without Diabetes Mellitus: a retrospective cohort study with propensity score matching', *Cardiovascular Diabetology*, 20(1), p. 140. doi: 10.1186/S12933-021-01336-0.
- Mbuzi, V., Fulbrook, P. and Jessup, M. (2018) 'Effectiveness of programs to promote cardiovascular health of Indigenous Australians: a systematic review'.
- Mitacchione, G. *et al.* (2021) 'Impact of prior statin use on clinical outcomes in COVID-19 patients: data from tertiary referral hospitals during COVID-19 pandemic in Italy', *Journal of Clinical Lipidology*, 15(1), pp. 68–78. doi: 10.1016/J.JACL.2020.12.008.
- Muhamad, S. A. *et al.* (2021) 'COVID-19 and Hypertension: The What, the Why, and the How', *Frontiers in Physiology*, 12. doi: 10.3389/FPHYS.2021.665064/FULL.
- Nägele, M. P. *et al.* (2020) 'Endothelial dysfunction in COVID-19: Current findings and therapeutic implications', *Atherosclerosis*. Elsevier Ireland Ltd, pp. 58–62. doi: 10.1016/j.atherosclerosis.2020.10.014.

- Nishiga, M. *et al.* (2020) ‘COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives’, *Nature Reviews Cardiology*. Nature Research, pp. 543–558. doi: 10.1038/s41569-020-0413-9.
- Oesterle, A., Laufs, U. and Liao, J. K. (2017a) ‘Pleiotropic Effects of Statins on the Cardiovascular System’, *Circulation Research*. doi: 10.1161/CIRCRESAHA.116.308537.
- Oesterle, A., Laufs, U. and Liao, J. K. (2017b) ‘Pleiotropic Effects of Statins on the Cardiovascular System’, *Circulation Research*. Lippincott Williams and Wilkins, pp. 229–243. doi: 10.1161/CIRCRESAHA.116.308537.
- Ortiz, A. *et al.* (2021) ‘Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA’, *Nephrology Dialysis Transplantation*, 36(1), p. 87. doi: 10.1093/NDT/GFAA314.
- People with Certain Medical Conditions | CDC* (no date). Available at: <https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html> (Accessed: 10 November 2021).
- Pinal-Fernandez, I., Casal-Dominguez, M. and Mammen, A. L. (2018) ‘Statins: pros and cons’, *Medicina Clinica*. Ediciones Doyma, S.L., pp. 398–402. doi: 10.1016/j.medcli.2017.11.030.
- Prabhakar, H., Kapoor, I. and Mahajan, C. (2020) *Clinical Synopsis of COVID-19: Evolving and Challenging*. Springer Singapore. Available at: <https://books.google.co.id/books?id=dUQBEEAAQBAJ>.
- Ritter, J. M. *et al.* (2019) *Rang and Dale’s Pharmacology*. Elsevier. Available at: <https://books.google.co.id/books?id=y-C9ugEACAAJ>.
- Rossi, R. *et al.* (2020) ‘Protective role of statins in COVID 19 patients: importance of pharmacokinetic characteristics rather than intensity of action’, *Internal and Emergency Medicine*. Springer Science and Business Media Deutschland GmbH, pp. 1573–1576. doi: 10.1007/s11739-020-02504-y.
- Rothan, H. A. and Byrareddy, S. N. (2020) ‘The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak’, *Journal of Autoimmunity*. doi: 10.1016/j.jaut.2020.102433.
- Saeed, O. *et al.* (2020) ‘Statin use and in-hospital mortality in patients with diabetes mellitus and covid-19’, *Journal of the American Heart Association*, 9(24). doi: 10.1161/JAHA.120.018475.
- Sanyaolu, A. *et al.* (2020) ‘Comorbidity and its Impact on Patients with COVID-19’, *Sn Comprehensive Clinical Medicine*, 2(8), p. 1. doi: 10.1007/S42399-020-00363-4.

- Shamseer, L. *et al.* (2015) 'Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015: Elaboration and explanation', *BMJ (Online)*. BMJ Publishing Group. doi: 10.1136/bmj.g7647.
- Sirtori, C. R. (2014) 'The pharmacology of statins', *Pharmacological Research*. Academic Press, pp. 3–11. doi: 10.1016/j.phrs.2014.03.002.
- Siyoto, S. and Sodik, M. A. (2015) *DASAR METODOLOGI PENELITIAN*. Literasi Media Publishing. Available at: <https://books.google.co.id/books?id=QPhFDwAAQBAJ>.
- SL, S. *et al.* (2020) 'Statin Use Is Associated with Decreased Risk of Invasive Mechanical Ventilation in COVID-19 Patients: A Preliminary Study', *Pathogens (Basel, Switzerland)*, 9(9), pp. 1–9. doi: 10.3390/PATHOGENS9090759.
- Sohrabi, C. *et al.* (2020) 'World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19)', *International Journal of Surgery*. Elsevier Ltd, pp. 71–76. doi: 10.1016/j.ijso.2020.02.034.
- Su, Y. B. *et al.* (2020) 'Cardiovascular manifestation and treatment in COVID-19', *Journal of the Chinese Medical Association*. Wolters Kluwer Health, pp. 704–709. doi: 10.1097/JCMA.0000000000000352.
- Subir, R., Jagat J, M. and Kalyan K, G. (2020a) 'Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19)', *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*, 14(5), pp. 1225–1229. doi: 10.1016/J.DSX.2020.07.011.
- Subir, R., Jagat J, M. and Kalyan K, G. (2020b) 'Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19)', *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*, 14(5), pp. 1225–1229. doi: 10.1016/j.dsx.2020.07.011.
- Tan, W. Y. T. *et al.* (2020) 'Statin use is associated with lower disease severity in COVID-19 infection', *Scientific Reports*, 10(1), pp. 1–7. doi: 10.1038/s41598-020-74492-0.
- Uman, L. S. (2011) 'Information management for the busy practitioner: Systematic reviews and meta-analyses', *Journal of the American Academy of Child and Adolescent Psychiatry*, 20(1), pp. 57–59. doi: 10.1016/j.revmed.2014.05.011.
- Wang, M. Y. *et al.* (2020) 'SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development', *Frontiers in Cellular and Infection Microbiology*. Frontiers Media S.A. doi: 10.3389/fcimb.2020.587269.

- Willim, H. A., Ketaren, I. and Supit, A. I. (2020) 'Dampak Coronavirus Disease 2019 terhadap Sistem Kardiovaskular'. doi: <https://doi.org/10.35790/ecl.8.2.2020.30540>.
- Yetmar, Z. A. *et al.* (2021) 'Association Between Chronic Statin Use and 30-Day Mortality in Hospitalized Patients With COVID-19', *Mayo Clinic Proceedings: Innovations, Quality & Outcomes*, 5(2), pp. 442–446. doi: 10.1016/j.mayocpiqo.2021.02.002.
- Zhang, W. (2020) *Covid-19: From Basics To Clinical Practice*. World Scientific Publishing Company. Available at: <https://books.google.co.id/books?id=tSn7DwAAQBAJ>.
- Zhang, X. J. *et al.* (2020) 'In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19', *Cell Metabolism*, 32(2), pp. 176-187.e4. doi: 10.1016/J.CMET.2020.06.015.